Buspirone improves 6-hydroxydopamine-induced catalepsy through stimulation of nigral 5-HT1a receptors in rats

Pharmacological Reports

Volumn 62, Issue 2, 2010, Pages 258-264

  Nayebi, Alireza M ^a,b   Rad, Siyamak R ^c   Saberian, Mehdi ^b   Azimzadeh, Saeid ^b   Samini, Morteza ^c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

6 hydroxydopamine; Buspirone; Catalepsy; Rat

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; BUSPIRONE; OXIDOPAMINE; SEROTONIN 1A RECEPTOR; SEROTONIN AGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG ACTIVITY; DRUG EFFECT; HISTOLOGY; MALE; NONHUMAN; PARKINSON DISEASE; RAT; SUBSTANTIA NIGRA; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; PHYSIOLOGY; WISTAR RAT;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; BUSPIRONE; CATALEPSY; MALE; OXIDOPAMINE; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN RECEPTOR AGONISTS; SUBSTANTIA NIGRA;

EID: 77953306586     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70264-4     Document Type: Article

References (38)

1. 1A receptor selective ligands, (R)-8 OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn Schmiedebergs Arch Pharmacol, 1993, 347, 353-362.
2. Ba M, Kong M, Ma G, Yang H, Lu G, Chen S, Liu Z: Cellular and behavioral effects of 5-HT1A receptor agonist 8-OH-DPAT in a rat model of levodopa-induced motor complications. Brain Res, 2007, 1127, 177-184.
3. Bara-Jimenez W, Bibbiani F, Morris MJ, Dimitrova T, Sherzai A, Mouradian MM, Chase TN: Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov Disord, 2005, 20, 932-936.
4. 1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease. Neurobiol Dis, 2006, 23, 77-86.
5. Bishop C, Krolewski DM, Eskow KL, Barnum CJ, Dupre KB, Deak T, Walker PD: Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats. J Neurosci Res, 2009, 87, 1645-1658.
6. 2 receptors to the ERK 1/2 map kinase pathway. J Com Neurol, 2006, 498, 415-430.
7. 2A receptor mRNA in human brain. Brain Res, 1995, 676, 157-168.
8. De Deurwaerdere P, Navailles S, Berg KA, Clarke WP, Spampinato U: Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J Neurosci, 2004, 24, 3235-3241.
9. 1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat. Neuropharmacology, 2008, 55, 1321-1328.
10. 1A receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Res, 2007, 1158, 135-143.
11. 1A receptors in Δ9-tetrahydrocannabinolinduced catalepsy-like immobilization in mice. Eur J Pharmacol, 2006, 550, 117-122.
12. Filip M, Bader M: Overview on 5-HT receptors and their role in physiology and pathology of the central nervous system. Pharmacol Rep, 2009, 61, 761-777.
13. Forjaz MJ, Rodriguez-Blázquez C, Martinez-Martin P; on behalf of the Longitudinal Parkinson's Disease Patient Study (Estudio Longitudinal de Pacientes con Enfermedad de Parkinson-ELEP) Group: Rasch analysis of the hospital anxiety and depression scale in Parkinson's disease. Mov Disord, 2008, 24, 525-531.
14. 1A agonist, in 6-hydroxydopamine lesioned rats. Psychopharmacology (Berl), 1988, 94, 178-182.
15. Goff DC, Midha KK, Brotman., McCormick S, Waites M, Mmico ET: An open trial of buspirone added to neuroleptics in schizophrenic patients, J Clin Psychopharmacol, 1991, 11, 193-197.
16. Gower AJ, Tricklebank MD: Alpha 2-adrenoceptor antagonist activity may account for the effects of buspirone in an anticonfilict test in the rat. Eur J Pharmacol, 1988, 155, 129-137.
17. 1A agonists with potential anxiolytic properties. J Pharmacol Exp Ther, 1988, 246, 745-752.
18. 1A receptors are linked to a G_-adenylate cyclase complex in rat hippocampus. Eur J Pharmacol, 1988, 154, 95-98.
19. 1A receptor agonist, potentiated S(-)-sulpirideinduced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. J Pharmacol Exp Ther, 1999, 291, 1227-1232.
20. Jadhav SA, Gaikwad RV, Gaonkar RK, Thorat VM, Gursale SC, Balsara JJ: Dose-dependent response of central dopaminergic systems to buspirone in mice. Indian J Exp Biol, 2008, 46, 704-714.
21. 1B receptors. J Pharmacol Exp Ther, 2000, 292, 1111-1117.
22. Lavoie B, Parent A: Immunohistochemical study of the serotoninergic innervations of the basal ganglia in the squirrel monkey. J Comp Neurol, 1990, 299, 1-16.
23. Lim LW, Temel Y, Visser-Vandewalle V, Steinbusch H, Schruers K, Hameleers R, Esquivel G et al.: Effect of buspirone on the behavioral regulation of rats in low versus high anxiety conditions. Arzneimittelforschung, 2008, 58, 269-276.
24. 2A/C antagonist, reverse haloperidol induced catalepsy in rats independently of striatal dopamine release. Psychpharmacology, 1997, 131, 57-63.
25. 1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopaminegenerated lesions. Brain Res, 2006, 1112, 126-133.
26. 1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson's disease. Psychopharmacology (Berl), 2007, 192, 49-59.
27. Mink JW: The basal ganglia: focused selection and inhibition of competing motor programs. Prog Neurobiol, 1996, 50, 381-425.
28. 1A receptor agonist for the treatment of L DOPA-induced dyskinesia. Brain, 2008, 131, 3380-3394.
29. Paquette MA, Foley K, Brudney EG, Meshul CK, Johnson SW, Berger SP: The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism. Psychopharmacology (Berl), 2009, 204, 743-754.
30. Paxinos G, Watson C: The rat brain in stereotaxic coordinates. Academic Press, Sydney, 1982.
31. Pires JGP, Bonikoski V, Futuro-Neto HA: Acute effects of selective serotonin reuptake inhibitors on neuroleptic-induced catalepsy in mice. Braz J Med Biol Res, 2005, 38, 1867-1872.
32. 1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur J Pharmacol, 2002, 453, 217-221.
33. Riad M, Garcia S, Watkins KC, Jodoin N, Doucet E, Langlois X, el Mestikawy S et al.: Somatodendritic localization of 5-HT1A and preterminal axonal localization of 5-HT1B serotonin receptors in adult rat brain. J Comp Neurol, 2000, 417, 181-194.
34. Scholtissen B, Verhey FRJ, Steinbusch HWM, Leentjens AFG: Serotonergic mechanisms in parkinson's disease: opposing results from preclinical and clinical data. J Neural Transm, 2006, 113, 59-73.
35. Tunnicliff G: Molecular basis of buspirone's anxiolytic action. Pharmacol Toxicol, 1991, 69, 149-156.
36. Wright DE, Seroogy KB, Lundgren KH, Davis BM, Jennes L: Comparative localization of serotonin1A, 1C and 2 receptor subtype mRNA in rat brain. J Comp Neurol, 1995, 351, 357-373.
37. Yu JG, Wu J, Shen FM, Cai GJ, Liu JG, Su DF: Arterial baroreflex dysfunction fails to mimic Parkinson's disease in rats. J Pharmacol Sci, 2008, 108, 56-62.
38. 1A agonist with antipsychotic- and antiparkinsonian-like properties. Neuropharmacology, 2006, 51, 129-140.